Boehringer Mannheim's new clot buster.
出版信息
Nat Biotechnol. 1997 Feb;15(2):114. doi: 10.1038/nbt0297-114a.
PMID:9035121
Abstract
摘要
相似文献
1
Boehringer Mannheim's new clot buster.
Nat Biotechnol. 1997 Feb;15(2):114. doi: 10.1038/nbt0297-114a.
2
New clot busters threaten Genentech's tPA.
Nat Biotechnol. 1997 May;15(5):405. doi: 10.1038/nbt0597-405.
3
On 'jumbo' and 'junkie' trials. A fumbled affair, a jungle, or the ultimate solution?关于“大型”和“成瘾性”试验。是一场混乱的事情、一片丛林，还是最终的解决方案？
Eur Heart J. 1991 Feb;12(2):101-2.
4
Laboratory and clinical experience with recombinant plasminogen activator.重组纤溶酶原激活剂的实验室及临床经验
Prog Clin Biol Res. 1986;211:303-13.
5
6
Genentech falls at the last fence in race to market heart drug.基因泰克在心脏药物上市竞赛中功败垂成。
Nature. 1987;327(6122):450. doi: 10.1038/327450a0.
7
Reteplase in acute myocardial infarction.瑞替普酶治疗急性心肌梗死
JAMA. 2004 May 26;291(20):2429-30; author reply 2430. doi: 10.1001/jama.291.20.2429-c.
8
Stenting versus thrombolysis in acute myocardial infarction trial (STAT).急性心肌梗死支架置入术与溶栓治疗对比试验（STAT）
Indian Heart J. 2001 May-Jun;53(3):375.
9
Primary angioplasty or t-PA for the management of acute myocardial infarction?直接血管成形术还是使用组织型纤溶酶原激活剂治疗急性心肌梗死？
J Fam Pract. 1999 Aug;48(8):577-8.
10
Tissue plasminogen activator after retinal artery occlusion.
Ophthalmology. 1999 Dec;106(12):2231-2. doi: 10.1016/S0161-6420(99)90565-1.
Zotero 插件